البلد: الاتحاد الأوروبي
اللغة: الإنجليزية
المصدر: EMA (European Medicines Agency)
Emapalumab
Swedish Orphan Biovitrum AB (publ)
L04AA39
emapalumab
Immune System Diseases
Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).
Refused